Roche Holding AG (OTCMKTS:RHHBY) has earned a consensus recommendation of “Hold” from the twelve brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $45.71.
Several research analysts recently weighed in on the company. Morgan Stanley reiterated an “equal weight” rating on shares of Roche in a research report on Thursday, June 10th. Societe Generale reissued a “hold” rating on shares of Roche in a report on Tuesday, July 27th. Cowen assumed coverage on Roche in a report on Wednesday, July 21st. They issued an “outperform” rating on the stock. Barclays set a $46.42 price objective on Roche and gave the company an “overweight” rating in a report on Friday, July 23rd. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Roche in a report on Monday, August 2nd.
RHHBY stock traded up $0.11 during trading on Wednesday, hitting $46.86. 781,520 shares of the company traded hands, compared to its average volume of 1,501,570. The stock’s 50-day simple moving average is $48.82 and its 200 day simple moving average is $45.10. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.30 and a quick ratio of 1.01. The company has a market cap of $320.05 billion, a PE ratio of 17.64, a P/E/G ratio of 2.32 and a beta of 0.34. Roche has a 1 year low of $39.72 and a 1 year high of $51.05.
Roche Company Profile
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process.
Further Reading: When can a hold rating present a buying opportunity?
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.